DSpace@İnönü

Yazar "Tabak, F" için listeleme

Yazar "Tabak, F" için listeleme

Sırala: Sıra: Sonuçlar:

  • Port-related Delftia Tsuruhatensis bacteremia in a patient with breast 
    Tabak, O; Mete, B; Aydin, S; Mandel, NM; Otlu, B; Ozaras, R; Tabak, F (2013)
    Delftia tsuruhatensis is a non-glucose fermenting, oxidase positive, motile, gram-negative bacillus first isolated from activated sludge collected from a domestic wastewater treatment plant in Japan. To the best of our ...
  • Withdrawal of Staphylococcus aureus from intensive care units in Turkey 
    Erdem, H; Dizbay, M; Karabey, S; Kaya, S; Demirdal, T; Koksal, I; Inan, A; Erayman, I; Ak, O; Ulu-Kilic, A; Karasahin, O; Akbulut, A; Elaldi, N; Yilmaz, G; Candevir, A; Gul, HC; Gonen, I; Oncul, O; Aslan, T; Azak, E; Tekin, R; Tufan, ZK; Yenilmez, E; Arda, B; Gungor, G; Cetin, B; Kose, S; Turan, H; Akalin, H; Karabay, O; Dogan-Celik, A; Albayrak, A; Guven, T; Celebi, G; Ozgunes, N; Ersoy, Y; Sirmatel, F; Oztoprak, N; Balkan, II; Bayazit, FN; Ucmak, H; Oncu, S; Ozdemir, D; Ozturk-Engin, D; Bitirgen, M; Tabak, F; Akata, F; Willke, A; Gorenek, L; Ahmed, SS; Tasova, Y; Ulcay, A; Dayan, S; Esen, S; Leblebicioglu, H; Altun, B; Unal, S (2013)
    Background: In the past, Staphylococcus aureus infections have displayed various patterns of epidemiologic curves in hospitals, particularly in intensive care units (ICUs). This study aimed to characterize the current trend ...
  • Colistin nephrotoxicity increases with age 
    Balkan, II; Dogan, M; Durdu, B; Batirel, A; Hakyemez, IN; Cetin, B; Karabay, O; Gonen, I; Ozkan, AS; Uzun, S; Demirkol, ME; Akbas, S; Kacmaz, AB; Aras, S; Mert, A; Tabak, F (2014)
    Background: Colistin (COL) has become the backbone of the treatment of infections due to extensively drug-resistant (XDR) Gram-negative bacteria. The most common restriction to its use is acute kidney injury (AKI). Methods: ...
  • ESTIMATION OF HEPATITIS C COSTS IN TURKEY VIA EXPERT OPINION: DELPHI 
    Ormeci, N; Akarca, U; Aladag, M; Balik, I; Kadayifci, A; Kalayci, C; Kaymakoglu, S; Koksal, I; Ozkan, H; Tabak, F; Saka, G (2014)
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Demographic Characteristics and Transmission Risk Factors of Patients 
    Tabak, F; Sirin, G; Demir, M; Aladag, M; Sumer, S; Kurtaran, B; Tosun, S; Yamazhan, T; Bozkurt, I; Gurbuz, Y; Batirel, A; Senates, E; Kandemir, FO; Topal, F; Doganay, HL; Sezgin, O; Mistik, R; Kose, S; Yilmaz, Y; Inan, D; Koksal, I; Parlak, E; Akdogan, M; Guner, R (2021)
    Objectives: To describe the prevalence of risk factors in patients infected with hepatitis C virus (HCV).